

P-2

Racial and ethnic disparities in US neuroendocrine tumor clinical trial enrollment over the past quarter century.

Xena X. Zheng¹, Akshee Batra², Joseph White³, Aman Chauhan².

¹Department of Medicine, University of Miami-Miller School of Medicine, Jackson Memorial Hospital, Miami, FL; ²Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, FL, USA; ³Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.

BACKGROUND

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms originating from neuroendocrine cells, with considerable variation in behavior and clinical presentation. The rising incidence of NETs has driven advancements in drug development; however, it remains unclear whether all demographic groups have equal access to novel therapeutic trials. Previous oncologic epidemiological studies have identified race-specific disparities in overall and disease-specific survival. This study aimed to assess whether similar racial and ethnic disparities exist in the enrollment of patients in NET clinical trials.

METHODS

We collected data from all completed NET clinical trials involving adult patients conducted in the United States over the past 25 years (1/1/2000 to 1/1/2025) as reported on clinicaltrials.gov. Therapeutic interventional trials were included while observational, non-interventional or non-therapeutic trials were excluded. Key study variables included race, ethnicity, sex, tumor type, and year of study. To assess enrollment patterns, we calculated the enrollment ratio for each racial and ethnic group, defined as the percentage of enrollees from each group divided by their proportion among the overall NET patient population.

RESULTS

We analyzed 64 NET trials, comprising 5,020 participants total. The gender distribution was similar, with 2,455 women and 2,565 men. Racial demographic data were reported in 60.9% (39/64) of the trials, while ethnicity data were provided in 42.2% (27/64). The reporting of race increased markedly, rising from 16.7% during 2008–2011 to 78.3% in 2020–2024. The comparison of enrollment ratios revealed that Black participants were significantly underrepresented compared to White participants (0.292, $p < 0.001$), and Hispanic participants were significantly underrepresented compared to Non-Hispanic participants (0.536, $p < 0.001$).




Table 1: Demographic Representation and Enrollment Ratios in NETs Clinical Trials

	Black	White	Hispanic	Non-Hispanic
NETs Patient Demographics	16.1%	74.0%	10.4%	89.6%
NETs Clinical Trial Enrollee Demographics	5.33%	83.5%	5.69%	91.3%
Enrollment Ratio	0.331	1.13	0.546	1.02
Relative Enrollment Compared with White	0.292 ($p < 0.001$)	1.00	-	-
Relative Enrollment Compared with Non-Hispanic	-	-	0.536 ($p < 0.001$)	1.00

CONCLUSIONS

Black and Hispanic Americans are significantly underrepresented in NET clinical trials. Clinical trials are critical for developing effective treatments and understanding how interventions perform across populations. The lack of representation hinders our ability to evaluate how NET therapies affect different racial and ethnic groups, potentially worsening existing health disparities. Enhancing the inclusion of underrepresented minorities in NET clinical trials is vital to promoting equitable care and improving health outcomes for all patients.

ABSTRACT ID 33487